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Summary
Background The 2013–15 Ebola virus disease epidemic in west Africa greatly accelerated the development of Ebola 
vaccine. We aimed to analyse the immune persistence induced by one shot of an adenovirus type-5 vector-based 
Ebola virus vaccine up to 6 months and the eﬀ ect of boosting with a homologous vector in healthy adults in China.
Methods In a randomised, double-blind, placebo-controlled, phase 1 clinical trial in one site in Jiangsu Province, 
China, 120 healthy adults aged 18–60 years received an initial dose of intramuscular adenovirus type-5 Ebola virus 
vaccine of 4·0 × 10¹⁰ viral particles, 1·6 × 10¹¹ viral particles, or placebo, and were followed up to day 168. Participants 
were subsequently re-recruited to receive a booster dose of the same vaccine or placebo, in the same dose, at month 6. 
Women who were pregnant, breastfeeding, or planned to become pregnant during the next month were excluded. 
Randomisation was conducted by computer-generated block randomisation. Randomisation data were unmasked for 
interim analysis of the data obtained between days 0–28 but not disclosed to participants or site staﬀ . Safety and 
immunogenicity analysis were done on the intention-to-treat population. We aimed to assess the safety proﬁ le of the 
experimental vaccine and the immunity responses to a single-dose immunisation or a homologous prime-boost 
regimen. Primary outcomes were Ebola glycoprotein-speciﬁ c ELISA antibody responses 28 days post-boost and the 
occurrences of adverse reactions post-boost. The original trial and the extended booster study were registered with 
ClinicalTrials.gov, numbers NCT02326194 and NCT02533791, respectively.
Findings Between Dec 28, 2014, and Jan 9, 2015, we enrolled 210 volunteers. 90 participants were not randomised due 
to not meeting inclusion criteria (61), meeting exclusion criteria (4), or withdrawal of consent (25). 120 people were 
randomly assigned to receive intramuscular Ebola vaccine at 4·0 × 10¹⁰ viral particles (low dose, n=40), Ebola vaccine 
at 1·6 × 10¹¹ viral particles (high dose, n=40), or placebo (n=40, in two groups of 20). After prime vaccination, the 
geometric mean titer (GMT) of ELISA EC90 peaked at 682·7 (95% CI 424·3–1098·5) in the low-dose vaccine group 
and 1305·7 (970·1–1757·2) in the high-dose vaccine group  at day 28, and then fell gradually through the next a few 
months to 575·5 (394·8–838·8) in the high-dose vaccine group and 197·9 (107·9–362·7) in the low-dose vaccine 
group at day 168. No speciﬁc response was recorded in the placebo group with a GMT of 5·0. Of the 120 participants 
involved in the initial trial, ten participants declined to participate, and 110 were included in the boost immunisation: 
38 received the low dose, 35 received the high dose, and 37 received the placebo. At day 28 after boost vaccination, the 
ELISA EC90 titres rapidly rose to 6110 (95% CI 4705–7935) in the low-dose group and to 11825 (8904–15705) in the 
high dose group. 78 of 110 participants reported at least one solicited adverse reaction within the ﬁ rst 7 days after 
booster administration. Both of the groups who received vaccine showed signiﬁ cantly higher incidence of mild or 
moderate solicited adverse reactions than did the placebo group.
Interpretation The adenovirus 5-vectored Ebola vaccine of 1·6 × 10¹¹ viral particles was highly immunogenic and 
safe. The lower dose  of 4·0 × 10¹⁰ viral particles was also safe, but immunogenicity seemed to be more vulnerable 
to the pre-existing immunity of adenovirus 5. A homologous priming-boosting regimen with adenovirus type-5 
Ebola vaccine at 6 months interval was able to elicit greater antibody responses with longer duration. These results 
support an immunisation strategy to implement a booster injection for a more durable protection against Ebola 
virus disease. 
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Introduction
 The 2013–15 Ebola virus disease epidemic in west Africa 
caused by subtype Zaire was the largest in history, spreading 
across borders and causing a total of 28 616 Ebola cases in 
Guinea, Liberia, and Sierra Leone, with 11 310 deaths.1 Ebola 
virus disease used to be deemed regional, and with few 
cases, the development of a vaccine did not get enough 
attention and progressed slowly. Since this recent outbreak, 
development of Ebola vaccine accelerated greatly, and 
clinical trials with various Ebola vaccine candidates were 
launched as an emergency response to this crisis.2–7 Most of 
these studies focused on introducing a quick protective 
response with a rapidly acting immunisation regimen.8 
However, following the end of the epidemic, more attention 
must be put in the durability of the vaccine-elicited 
protection and the potential beneﬁ ts of a booster injection.
In October, 2014, we launched a ﬁ rst-in-human trial 
with a novel recombinant adenovirus type-5 vector-based 
Ebola vaccine expressing the glycoprotein of Ebola.7 In 
the preliminary report of this trial, antibody responses 
elicited by the experimental adenovirus type-5 Ebola 
virus vaccine have been assessed up to day 28 after 
vaccination. However, the durability of a single-dose 
recombinant adenovirus type-5 Ebola virus vaccine 
immunisation is still unknown, and we must assess 
whether subsequent boosts will be necessary to maintain 
or establish suﬃ  cient long-term immunity.9 In this 
Article, we describe the immune dynamics induced by 
one dose of the adenovirus type-5 Ebola virus vaccine up 
to 6 months and the boosting responses to a homologous 
vector vaccine in healthy adults in China.
Methods
Study design and participants
 We did a randomised, double-blind, placebo-controlled, 
phase 1 clinical trial at one phase 1 vaccine clinical trial 
site in Taizhou City, Jiangsu Province, China, from 
Dec 28, 2014.7 120 healthy adults of both sexes between 
the ages of 18 and 60 years were randomly assigned to 
receive an injection of experimental adenovirus type-5 
Ebola virus vaccine or placebo. Women who were 
pregnant, breastfeeding, or planned to become pregnant 
during the next month were excluded. After injection, all 
the participants were followed up for 6 months. We 
added an extending study for a homologous booster 
vaccination at month 6 after the prime injection by 
protocol amendment. Participants who were involved in 
the initial study were re-recruited and assessed for 
eligibility. Approval of the modiﬁ ed study protocol was 
obtained from the ethics committee of the Jiangsu 
Provincial Center for Disease Control and Prevention 
before the implementation of the extended boosting 
Research in context
Evidence before this study
We searched PubMed for clinical trial reports with the terms 
“Ebola” or “Ebolavirus”, and “vaccine”, and ClinicalTrials.gov for 
unpublished randomised trials with no date or language 
restrictions, up to Aug 17, 2016. Since the 2014 Ebola outbreak, a 
total of 46 clinical trials with various Ebola vaccines candidates 
were launched according to the registration on Clinicaltrial.gov 
and Pan African Clinical Trials Registry. Up to now, only 
three heterologous prime-boost studies have been reported. 
Results from these trials indicated that some of the heterologous 
prime-boost combinations could be powerfully immunogenic in 
elicitation of both anamnestic antibody responses and robust 
T-cell responses, but some of them were not. An open-label, 
cluster-randomised ring vaccination trial with a rVSV-ZEBOV in 
Guinea showed a high eﬃ  cacy in preventing Ebola virus disease.
A novel adenovirus type-5 Ebola virus vaccine expressing the 
glycoprotein of the 2014 epidemic strain was assessed in a 
phase 1 clinical trial in China, of which safety and immunogenicity 
data up to day 28 after injection was published in a preliminary 
report. However, the durability of a single dose recombinant 
adenovirus type-5 vaccination is still unknown, and assessment 
of whether subsequent boosts will be necessary to maintain or 
establish suﬃ  cient long-term immunity will be important.
Added value of this study
This report includes the follow-up data from the ﬁrst phase 1 
study of the adenovirus type-5 Ebola virus vaccine in Chinese 
adults up to day 168, and an extra boosting study with a 
homologous vaccine at a prime-boost interval of 6 months. 
The humoral responses were followed up to month 12 after 
boost vaccination. Although strong immune responses were 
noted after the one-short regimen of adenovirus type-5 Ebola 
virus vaccine, especially with the high dose, a quick waning of 
the antibodies were observed during day 56–168. 
The homologous prime-boost regimen at month 6 was safe 
and highly immunogenic. We observed superior antibodies 
responses induced by the homologous prime-boost regimen to 
those induced by prime dose alone. However, the boosting 
eﬀ ects of speciﬁ c T-cell responses by the homologous 
prime-boost regimen seemed small in this study.
Implications of all the available evidence
Adenovirus type-5 Ebola virus vaccine is safe and 
immunogenic, but the short duration of antibodies raised a 
need for prime-boost immunisation. A priming-boosting 
regimen with homologous adenovirus type-5 vector-based 
Ebola virus vaccine could elicit greater humoral responses, but 
little cellular immunity response. In future studies, other 
boosting schedules with a booster vaccination at other 
prime-boost intervals or with a heterologous Ebola vaccine 
should be investigated, to provide a longer duration of high 
protection against Ebola virus. 
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immunisation. Separate written informed consent for 
the booster study was obtained from each participant. 
Full details of the study are provided in the protocol 
online. The studies were conducted in accordance with 
the Declaration of Helsinki and Good Clinical Practice.
Randomisation and masking
 In the initial study, the participants were sequentially 
enrolled in a two-step manner, and randomly assigned in 
a 2:1 ratio by computer-generated clock randomisation 
list to receive the adenovirus type-5 Ebola virus vaccine 
containing either 4 ·0 × 10¹⁰ (low dose, 40 people) viral 
particles or placebo, or to receive the vaccine containing 
1·6 × 10¹¹ (high dose, 40 people) viral particles or placebo 
(40 people), as described in a preliminary report.7 Both 
the vaccine and placebo were vialled and had identical 
packaging with a labelled randomisation code as the only 
identiﬁer. We unblinded the allocation of the participants 
for an interim analysis of the data obtained between 
day 0 and 28. However, the treatment allocation was not 
disclosed to both the participants and site staﬀ . At the 
end of the 6-month follow-up period of the initial study, 
we re-recruited the participants for the following booster 
study. Ten people declined to participate in the booster 
trial (two low-dose vaccine, ﬁ ve high-dose vaccine, three 
placebo) No additional randomisation was implemented, 
and participants who received the booster received the 
same dose as their original vaccination. The participants 
and the staﬀ  who assessed adverse events after 
immunisation or performed antibody detection in the 
laboratory were masked to the treatment allocation 
during the whole study.
Procedures
 The adenovirus type-5 Ebola virus vaccine consists of a 
recombinant replication defective adenovirus type-5 
vector expressing the glycoprotein of Ebola Zaire 
Makona variant (GenBank No. KJ660346). Each dose of 
the vaccine contains 4·0 × 10¹⁰ adenovirus type-5 viral 
particles. The placebo contains the vaccine excipients 
only without any adenovirus type-5 vectors. Participants 
were tested for any laboratory abnormal changes at 
protocol-speciﬁ ed study visits, and followed up for 
28 days for any adverse events after the prime 
vaccination, as described previously in a preliminary 
report.7 In the extended boosting study, participants 
were re-recruited and received the same vaccine as the 
initial treatment allocation. Thus, the participants in the 
high-dose vaccine group in the initial study were 
vaccinated with the adenovirus type-5 Ebola virus 
vaccine of 1·6 × 10¹¹ viral particles by receiving two shots 
of the vaccine (with one shot in each arm); the 
participants in the low-dose vaccine group in the initial 
study were vaccinated with a single shot of the 
adenovirus type-5 Ebola virus vaccine of 4·0 × 10¹⁰ viral 
particles; and the participants in the placebo group in 
the initial study still received placebo. Solicited adverse 
reactions were followed up within the ﬁ rst 7 days, and 
unsolicited adverse events were recorded up to day 28 
after the booster vaccination. Additionally, a self-report 
system for the serious adverse events was implemented 
during the whole study period from the priming 
vaccination at day 0 to the end of the booster study.
Besides the ﬁ ve visits between day 0 and day 28, which 
have already been reported in the previous preliminary 
report,7 participants received another ﬁ ve visits in the 
following study, including visits at day 56, 112, and 
168 after the priming, and visits at day 28 and month 12 
after the boosting. Blood samples were donated for 
antibody measurement at each visit. We assessed Ebola-
speciﬁ c antibody responses against the vaccine-matched 
glycoprotein with ELISA in terms of background 
subtracted ELISA 90% eﬀ ective concentration (ELISA 
EC90),3 and the antigen-speciﬁ ed T-cell responses with 
intracellular cytokine staining assay and Enzyme-Linked 
ImmunoSpot (ELISpot). The neutralising antibody titres 
against human adenovirus type-5 were measured by 
using a serum neutralisation assay at the speciﬁ ed time 
points both before and after vaccination.10
Outcomes
Primary outcomes were Ebola glycoprotein-speciﬁ c ELISA 
antibody responses 28 days post-boost and the occurrences 
of adverse reactions post-boost. The safety outcomes were 
measured by the incidence of solicited adverse reactions 
within 7 days, unsolicited adverse events within 28 days 
after the booster vaccination, and any occurrence of 
serious adverse events during the whole follow-up period. 
We did severity grading of the adverse events according to 
the standard guidelines issued by China state Food and 
Drug Administration.11 Laboratory analyses of blood were 
performed at day 56 post-vaccination for blood routine 
tests, biochemical tests, and coagulation function tests for 
analysis of safety outcomes.
Immunogenicity outcomes included the percentage of 
vaccine responders and the magnitude of the humoral 
and cellular immune responses against Ebola glycoprotein 
at speciﬁ c timepoints both after the priming and boosting 
vaccinations. The durations of speciﬁ c immune responses 
were assessed up to 6 months after the prime vaccination, 
and 12 months after the booster injection.
Statistical analysis
 We estimated a sample size of 40 per group would 
produce preliminary data for the incidence of adverse 
reactions and allow us to identify a 50% higher proportion 
of positive immune response post-vaccination in at least 
one vaccine group than in the placebo group with a 
power of 90%.
We analysed the safety endpoints based on the 
intention-to-treat cohort, in which all participants who 
received an injection were included, and the 
immunogenicity based on a per-protocol cohort in 
which those who did not complete all required visits or 
For the protocol see http://www.
jscdc.cn/jgzn/zzjg/ymlcpjs/
ymlcpjs_gzdt/201612/
P020161220410594669984.
pdf
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blood tests were excluded.  The stratiﬁ ed analysis of the 
immune responses after the prime dose up to day 168 
were done according to the baseline adenovirus type-5 
neutralising antibody titres of participants (low or 
negative ≤1:200 or high >1:200), while the boosting 
responses were stratiﬁ ed based on the adenovirus type-5 
neutralising antibody titres on day 168 before the boost 
injection (low or negative ≤1:200 or high >1:200). T-cell 
intracellular cytokine staining data of diﬀ erent 
treatment groups were analysed and displayed by using 
SPICE (version 5.3.5). Chi-square or Fisher’s exact test 
was used for categorical data, and the multiple 
comparisons were performed based on a Bonferroni-
adjusted alpha when there was a signiﬁ cant diﬀ erence 
across the treatment groups. Analysis of variance was 
used for the log-transformed antibody titres, while 
Wilcoxon  rank-sum test was used for abnormal data. 
Student-Newman-Keuls test was used for multiple 
comparisons between paired treatment groups when 
relevant. All statistical tests were two-sided with α=0·05 
and performed by an independent statistician using 
Figure 1: Trial proﬁ les of the initial study and the booster study.
High-dose vaccine= adenovirus type-5 Ebola virus vaccines of 1·6 × 10¹¹ viral particles. Low-dose vaccine=adenovirus type-5 Ebola virus vaccines of 4·0×10¹⁰ viral particles.
Placebo
(n=37)
Low dose: 
4 × 10¹⁰ VP 
(n=38)
High dose: 
1·6 × 10¹¹ VP 
(n=35)
Mean age (years) 43·9, SD 11·3 44·0, SD 9·6 44·1, SD 9·2
Sex
Male 17 19 17
Female 20 19 18
BMI (kg/m²) 24·2, SD 2·3 23·7, SD 2·3 24·3, SD 2·9
Adenovirus type-5 antibody titres before prime
>1:200 21 20 21
≤1:200 16 18 14
Adenovirus type-5 antibody titres before boost*
>1:200 21 26 30
≤1:200 16 12 5
Data are n unless otherwise speciﬁ ed. VP=viral particles. BMI=body-mass index. 
*Signiﬁ cant diﬀ erence of the adenovirus type-5 antibody titres at the time before 
boost was noted across the treatment groups. 
Table 1: Demography characteristics and adenovirus type-5 neutralising 
antibody titres in participants involved in the booster study
210 participants assessed for eligibility
60 in group 1 randomised 60 in group 2 randomised
In
it
ia
l s
tu
dy
Bo
os
te
r v
ac
ci
na
ti
on
40 allocated low-dose vaccine 
40 completed all visits in the 
  6-month period of follow-up
20 completed all visits in the 
  6-month period of follow-up
Low-dose vaccine 
 38 included in safety analysis
 37 included in immunogenicity analysis 
High-dose vaccine
 35 included in safety analysis
 35 included in immunogenicity analysis
Placebo
 37 included in safety analysis
 37 included in immunogenicity analysis
90 not randomised
 61 did not meet inclusion criteria
 4 met exclusion criteria
 25 withdrew consent
20 allocated placebo 40 allocated high-dose vaccine 
40 completed all visits in the 
  6-month period of follow-up
20 completed all visits in the 
  6-month period of follow-up
20 allocated placebo
40 eligible for booster vaccination
2 declined 1 declined 5 declined 2 declined
20 eligible for booster vaccination 40 eligible for booster vaccination 20 eligible for booster vaccination
38 received low-dose vaccine 19 received placebo 35 received high-dose vaccine 18 received placebo 
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SAS (version 9.3). A ﬁ ve-member external data and 
safety monitoring board was built for the safety data 
monitoring of this trial (see protocol).
The initial trial and the added boosting study were 
registered with ClinicalTrials.gov, numbers NCT02326194 
and NCT02533791, respectively.
Role of the funding source
 The funders of the study were involved in protocol 
design, but had no role in clinical data collection, safety 
monitoring, statistical analysis, data interpretation, or 
writing of the report. All the authors had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
 Between Dec 28, 2014, and Jan 9, 2015, we enrolled 
210 volunteers. 90 participants were not randomised 
due to not meeting inclusion criteria (61), meeting 
exclusion criteria (4), or withdrawal of consent (25). 
120 participants received either adenovirus type-5 Ebola 
virus vaccine of 4·0 × 10¹⁰ viral particles, adenovirus 
type-5 Ebola virus vaccine of 1·6 × 10¹¹ of viral particles, 
or placebo as prime immunisation at day 0, in the initial 
study, with 40 participants in each treatment group. The 
compliance of participants with the visits following 
vaccination was perfect up to the end of 6-month follow-
up at day 168 (ﬁ gure 1). In July, 2015, we invited all the 
120 participants for a booster study 6 months after 
prime vaccination, and 110 agreed to participate. Ten 
participants declined to receive booster injection, with 
two in the low-dose group, ﬁ ve in the high-dose group, 
and three in the placebo group. Baseline characteristics 
of participants who were involved in the booster study 
are described in table 1. Among them, 109 participants 
donated blood samples at day 28 after booster injection, 
and 102 participants donated blood samples at month 12 
after the booster injection. Another four participants 
Placebo group 
(n=37)
Low-dose 
group 
(n=38)
High-dose 
group 
(n=35)
P value*
Solicited adverse reactions within 0–7 days
Any 16 29 33 <0·0001†
Grade 1 13 24 24 0·0085‡
Grade 2 2 4 9 0·0338§
Grade 3 1 1 0 1·0000
Injection-site adverse reactions
Any 11 27 30 <0·0001||
Pain
Grade 1 4 19 29 <0·0001¶
Grade 2 1 3 1 0·6166
Induration
Grade 1 0 0 8  0·0001**
Redness
Grade 1 5 4 9 0·1825
Grade 2 1 0 2 0·2074
Grade 3 0 1 0 1·0000
Swelling
Grade 1 0 3 4 0·1082
Grade 2 1 1 0 1·0000
Grade 3 1 0 0 0·6545
Itch
Grade 1 0 1 0 1·0000
Any 8 10 15 0·1202
Fever
Grade 1 7 7 8 0·8760
Grade 2 0 0 6 0·0008**
Headache
Grade 1 0 1 0 1·0000
Grade 2 0 0 1 0·3182
Fatigue
Grade 1 0 0 3 0·0303**
Grade 2 0 1 1 0·7655
(Table 2 continues in next column)
Placebo group 
(n=37)
Low-dose 
group 
(n=38)
High-dose 
group 
(n=35)
p value*
(Continued from previous column)
Vomiting
Grade 1 1 0 0 0·6545
Diarrhoea
Grade 1 0 1 1 0·7655
Muscle pain
Grade 1 0 1 0 1·0000
Grade 2 0 0 1 0·3182
Joint pain
Grade 2 0 1 0 1·0000
Throat pain
Grade 1 0 1 1 0·7655
Cough
Grade 1 0 1 1 0·7655
Unsolicited adverse events within 0–28 days
Any 12 9 5 0·1938
Grade 1 8 6 2 0·1546
Grade 2 4 2 3 0·6934
Grade 3 0 1 0 1·0000
Data are n=number of participants. Grade 1 was a mild reaction, grade 2 was a 
moderate reaction, and grade 3 was a severe reaction (ie, prevented activity). 
*p values were generated from the comparison across the three groups. When 
signiﬁ cant diﬀ erence across treatment groups was found, we further applied 
pairwise comparisons on the basis of an adjusted α=0·017. †Both the high-dose 
and low-dose groups showed higher incidences than did placebo group. ‡Both 
the high-dose and low-dose groups showed higher incidences than did placebo 
group. §The high-dose group had a higher incidence than did the placebo group; 
||Both the high-dose and low-dose groups showed higher incidences than did 
placebo group. ¶The high-dose group showed a higher incidence than did the 
low-dose group, while both the high-dose and low-dose groups showed higher 
incidences than did placebo group. **The high-dose group showed a higher 
incidence than did the low-dose group and the placebo group.
Table 2: Solicited adverse reactions and unsolicited adverse events 
reported after the booster immunisation 
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(one in placebo group and three in the high-dose vaccine 
group) did not receive the booster injection but donated 
blood samples at the last visit (18 months after the 
prime vaccination).
 Laboratory adverse events were detected in 
7 participants at day 56, with 4 in the low-dose group 
and 3 in the placebo group, which were all mild and 
clinically insigniﬁ cant (appendix p 1). Among the 
110 participants who received the booster dose, 78 (71%) 
reported at least one solicited adverse reaction within 
the ﬁ rst 7 days, with a similar overall incidence to that 
observed after initial vaccination.7 The occurrence of 
solicited adverse reactions diﬀ ered signiﬁcantly between 
treatment groups with p<0·0001 (table 2). Both the 
high-dose and low-dose vaccine groups showed 
signiﬁ cantly higher incidences of mild or moderate 
solicited adverse reactions than did the placebo group. 
The most common injection-site reaction was pain, 
while the most common systemic adverse reaction was 
fever. Participants who received high-dose vaccine 
reported higher incidences of pain, induration, fever, 
and fatigue, than did those who received placebo. All 
6 moderate fever events were found in the high-dose 
group. However, the occurrence of severe adverse 
Overall Pre-existing adenovirus type-5
antibody titres ≤1:200*
Pre-existing adenovirus type-5
antibody titres >1:200*
n GMT Responders n GMT Responders n GMT Responders
Day 56
Placebo group 40 5·0 0 16 5·0 0 24 5·0 0
Low-dose group 40 489·8 
(295·3–812·3)
37 18 1163·3 
(303·0–5283·0)
18 22 241·3 
(5·0–3465·0)
19
High-dose group 40 1282·9 
(998·6–1648·3)
40 15 2290·1 
(1268·0–7220·0)
15 25 906·2 
(305·4–5802·0)
25
p value <0·0001† <0·0001‡ <0·0001† <0·0001† <0·0001† <0·0001‡
Day 112
Placebo group 40 5·0 0 16 5·0 0 24 5·0 0
Low-dose group 40 386·4 
(252·7–591·0)
38 18 780·3 
(189·9–4227·0)
18 22 217·4 
(5·0–3159·0)
20
High-dose group 40 856·8 
(662·9–1107·4)
40 15 1538·2 
(720·5–6010·0)
15 25 603·1 
(142·4–4576·0)
25
p value <0·0001† <0·0001‡ <0·0001† <0·0001† <0·0001† <0·0001‡
Day 168
Placebo group 40 5·0 0 16 5·0 0 24 5·0 0
Low-dose group 40 197·9 
(107·9–362·7)
34 18 539·2 
(262·5–1107·8)
17 22 87·1
(38·4–197·4)
17
High-dose group 40 575·5 
(394·8–838·8)
39 15 1216·2 
(978·6–1511·4)
15 25 367·3 
(217·7–619·7)
24
p value <0·0001† <0·0001† <0·0001† <0·0001‡ <0·0001† <0·0001‡
Day 28 after boost
Placebo group 37 5·0 0 16 5·0 0 21 5·0 0
Low-dose group 37 6110·3 
(4705·4–7934·6)
37 17 7553·3 
(5090·6–11 207·4)
17 20 5102·7 
(3558·6–7316·7)
20
High-dose group 35 11 824·9 
(8903·6–15704·8)
35 14 15680·0 
(11 041·5–22 267·0)
14 21 9797·1 
(6475·8–14821·9)
21
p value <0·0001† <0·0001† <0·0001† <0·0001† <0·0001† <0·0001†
Month 12 after boost
Placebo group 34 5·0 0 14 5·0 0 20 5·0 0
Low-dose group 33 674·1 
(505·9–898·2)
33 16 840·1 
(555·5–1270·4)
16 17 547·9 
(361·8–829·8)
17
High-dose group 35 856·8 
(573·8–1279·2)
34 14 1314·5 
(1022·3–1690·2)
14 21 644·0 
(339·6–1221·5)
20
p value <0·0001‡ <0·0001‡ <0·0001† <0·0001† <0·0001‡ <0·0001‡
GMT=geometric mean titre. n=number of participants. Ebola antibody EC90 measured by ELISA, according to treatment groups and timepoints. Optical density was read at 
450 nm. A positive Ebola speciﬁ c antibody response was deﬁ ned as the EC90 10 or more. For Ebola ELISA antibody  EC90 less than 10, a value of 5 was used for GMT calculation. 
*The stratiﬁ ed analyses of the immune responses were performed according to the baseline adenovirus type-5 neutralising antibody titres of participants before the prime 
injection. †The pairwise comparisons showed a signiﬁ cantly higher response level in the high-dose group compared with that in the low-dose group, and both the high-dose 
and low-dose groups showed a signiﬁ cantly higher responses than did the placebo group. ‡Both the high-dose and low-dose groups showed signiﬁ cantly higher responses 
than did the placebo group, but no signiﬁ cant diﬀ erence was noted between the high-dose and low-dose groups.
Table 3: ELISA antibody responses to the Ebola glycoprotein after initial and boost vaccination 
See Online for appendix
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reactions was not signiﬁ cantly diﬀ erent across groups. 
Two severe adverse reactions (grade 3) were noted, one 
swelling at injection site in the high dose group and one 
with redness at injection site in the low dose group 
(table 2). The incidences of unsolicited adverse events 
after boost vaccine were similar between treatment 
groups in the 28 day follow-up period after boost. No 
safety concerns were found associated with the anti-
adenovirus type-5 neutralising antibodies at the time of 
boost (appendix p 2).
Figure 2: Ebola-speciﬁ c ELISA EC90 titres to glycoprotein
GMT= geometric mean titre (A) all participants, (B) patients with baseline adenovirus type-5 neutralising antibody titres , (C) patients with baseline adenovirus 
type-5 neutralising antibody titres >1:200.
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Two serious adverse events were reported during the 
study period, including one case of pneumonia that 
occurred in the high-dose vaccine group 5 months after 
the prime vaccination and one case of duodenal ampulla 
ulcers in the low-dose vaccine group reported 2 weeks after 
the booster injection. Both events were cured after hospital 
treatment and deemed unrelated to the vaccination.
Ebola glycoprotein-speciﬁc ELISA titres are shown in 
table 3 and ﬁ gure 2. After prime vaccination with 
adenovirus type-5 Ebola virus vaccines, we found that 
ELISA EC90 titres increased signiﬁcantly at day 14 and 
peaked at day 28 in both high-dose and low-dose vaccine 
groups (682·7 [95% CI 424·3–1098·5] in the low-dose 
vaccine group and 1305·7 [970·1–1757·2] in the high-dose 
vaccine group  at day 28), whereas no speciﬁc response 
was recorded in the placebo group. The data at day 14 and 
28 after prime vaccination was reported in the preliminary 
report.7 ELISA EC90 titres of the low-dose and high-dose 
vaccine groups fell gradually, with a geometric mean titre 
(GMT) of 489·8 (95% CI 295·3–812·3) and 1282·9 
Figure 3: Glycoprotein-speciﬁc T-cell response measured by Enzyme-Linked ImmunoSpot at diﬀ erent time points before and after prime and boost 
vaccination
(A) IFN-γ expressing T cells per 10⁶ PBMC. (B) proportion of participants with a positive response of IFN-γ expressing T cells. IFN=interferon. PBMC=peripheral blood 
mononuclear cells. 
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(998·6–1648·3) at day 56, 386·4 (252·7–591·0) and 856·8 
(662·9–1107·4) at day 112, and 197·9 (107·9–362·7) and 
575·5 (394·8–838·8) at day 168. No Ebola glycoprotein-
speciﬁ c response was observed in the placebo group. The 
GMT of the ELISA EC90 titres for  the placebo group was 
5·0 throughout the whole study period. The high-dose 
group showed signiﬁ cantly higher and more sustainable 
ELISA EC90 titres in terms of GMTs than did the low-dose 
group throughout the 6-month follow-up period. 
However, no diﬀ erence in the proportion of the positive 
responders was found between the high-dose and low-
dose groups. Presence of high pre-existing adenovirus 
type-5 neutralising antibodies not only weakened the 
vaccine-elicited glycoprotein-speciﬁc antibody responses, 
but also accelerated the decay of ELISA EC90 titres, 
especially in the participants receiving the low dose. On 
the contrary, participants with naive or low baseline anti-
adenovirus type-5 neutralising antibodies showed only a 
slight waning of antibody titres, indicating a good 
durability of the antibody response after a single-dose 
vaccination. The Ebola glycoprotein-speciﬁc ELISA titres 
observed after the high-dose vaccination in the individuals 
with high baseline anti-adenovirus type-5 neutralising 
antibodies were similar to those observed after the low 
dose in those individuals with low baseline anti-
adenovirus type-5 neutralising antibodies.
Positive responses of speciﬁc CD4 and CD8 T cells in 
participants receiving vaccines peaked at day 14 after 
prime vaccination, and then declined gradually during 
the following period of study (appendix p 3). No 
signiﬁ cant diﬀ erence of the CD4 and CD8 T-cell 
responses was noted between the vaccine group and the 
placebo group at day 168. The medians of background 
subtracted spot-forming cells per 1 × 10⁶ cells were weak, 
with only 5 (IQR 0·0–11·7) in the low-dose vaccine group 
and 10 (3·3–33·3) in the high-dose vaccine group at 
day 168 (ﬁ gure 3). Double or triple cytokine positive 
speciﬁc CD4 and CD8 T-cell responses also decreased, 
but remained detectable in both vaccine groups up to 
168 days after the prime vaccination (appendix p 4).
A boosting vaccination with homologous vaccine at 
month 6 after the prime immunisation elicited strong 
humoral immune responses to Ebola glycoprotein 
regardless of the pre-existing immunity to the adenovirus 
type-5 at the time of boost (ﬁ gure 2 and appendix p 5). 
The glycoprotein speciﬁ c antibodies to the boost dose 
were superior to those induced by a single shot of 
priming vaccination alone. At day 28 after boost 
vaccination, the ELISA EC90 titres rapidly rose by over 
30 times to 6110 (95% CI 4705–7935) in the low-dose 
group and 20 times to 11 825 (8904–15 705) in the high-
dose group compared with pre-boost (table 3). No Ebola 
glycoprotein-speciﬁ c response was observed in the 
placebo group. The GMT of the ELISA EC90 titres for 
placebo group was 5.0 throughout the whole study 
period. The recipients of high-dose vaccine of 
1·6 × 10¹¹ viral particles showed stronger post boost 
antibody titres than the recipients of low-dose vaccine 
did. However, Ebola glycoprotein-speciﬁc ELISA EC90 
titres declined gradually after the peak, with GMTs of 
674·1 (95% CI 505·9–898·2) in the low-dose vaccine 
group and 856·8 (573·8–1279·2) in the high-dose vaccine 
group at month 12 after boost, which were signiﬁ cantly 
higher levels than those at month 6 after initial 
vaccination. Contrarily, three high-dose recipients in the 
initial prime study who did not receive the booster 
injection showed ELISA EC90 titres ranging from 152 to 610 
with an average of 285·5 at the same timepoint.
The speciﬁc T-cell responses quantiﬁed by interferon-γ 
(IFN-γ) showed a moderate increase after the booster 
injection, with 23·3 spot-forming cells (IQR 16·7–90·0) 
in the low-dose group and 95·0 spot-forming cells 
(63·3–196·7) in the high-dose group, which was 
signiﬁ cantly higher than those in the placebo group 
(ﬁ gure 3). Although the booster elicited greater IFN-γ 
expression by T cells than that showed at day 168 before 
boosting, the magnitude of responses was signiﬁ cantly 
lower than that observed at day 28 after initial vaccination.
The adenovirus type-5 neutralising antibody titres 
against the vaccine vector peaked at day 14 after the 
priming vaccination, and then waned gradually during 
the next 6 months. Although the boost immunisation 
with a homologous vaccine also boosted the 
anti-adenovirus type-5 neutralising antibody titres, 
antibody titres after the boost were not as high as those 
after the initial dose and declined quickly during the 
following 12 months (appendix p 6–7).
Discussion
 Our results suggest that the adenovirus type-5 Ebola virus 
vaccine of 1·6 × 10¹¹ viral particles was highly immunogenic 
for all participants, including those with a positive 
adenovirus type-5 baseline in healthy adults in China. 
Although a higher incidence of injection-site reactions was 
associated with the higher dose of the adenovirus 5-vectored 
Ebola vaccine, no severe safety concerns were raised. In a 
preclinical challenge study with non-human primates 
(NHPs) immunised with adenovirus 5-vectored Ebola 
vaccine, a titre of 1000 or higher showed 77% protection 
against death.12 Assuming that the value of 1000 in the 
ELISA is the level of protection for human beings, the 
high-dose adenovirus type-5 Ebola vaccine of 1·6 × 10¹¹ viral 
particles was able to induce high glycoprotein-speciﬁ c 
antibody response, indicating a signiﬁ cant protection to 
vaccinated human beings, at least for a short time 
(2–3 months based on these data).
The concerns ober the duration of protection against 
Ebola virus conferred by the vaccine were also ﬁ rst raised 
in NHPs challenge studies, which showed that the 
humoral and cellular immunity waned gradually over 
time, and protection was lost.12–14 In our trials, we observed 
a signiﬁ cant waning of the glycoprotein-speciﬁ c antibodies 
in vaccine recipients within 6 months after the initial 
vaccination. The vaccine-elicited immune response 
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against Ebola virus could also be compromised by the pre-
existing neutralising antibodies against the vaccine vector 
of adenovirus type-5. Although a single-dose regimen of 
protective vaccine would be much preferable for reactive 
immunisation against Ebola outbreaks and easier to 
administer in outbreak regions, a boost immunisation 
strategy is recommended to prolong the protection. Three 
studies adopted heterologous prime-boost regimens, 
including two using chimpanzee adenovirus 3-vectored 
Ebola vaccine (ChAd3-EBO-Z) as prime and then boosted 
with modiﬁed vaccinia Ankara-vectored Ebola (MVA-BN-
Filo) vaccine at the diﬀ erent dosages, and one using 
adenovirus type–26 vectored Ebola vaccine (Ad26.ZEBOV) 
or MVA-BN-Filo as prime and then boosted with the 
alternative vaccine.15–17 Results from these studies showed 
that both heterologous vector vaccines regimens of 
ChAd3-EBO-Z priming and Ad26.ZEBOV priming could 
elicit strong immune responses to Ebola virus that were 
superior to those induced by single dose prime vaccination 
alone, but a relatively low response to MVA-BN-Filo prime 
schedule with Ad26.ZEBOV boost was noted.
 We adopted a homologous prime-boost regimen in this 
booster study simply because the adenovirus type-5 Ebola 
virus vaccine is the only approved Ebola vaccine candidate 
for clinical trials in China. Considering that the boosting 
eﬀ ect with a homologous vaccine could be aﬀ ected by 
high anti-adenovirus type-5 neutralising antibodies 
elicited by the prime dose, the booster dose was 
administered at a 6-month interval to avoid the peak of 
antibodies against the vaccine vector induced by initial 
vaccination. After the booster vaccination, signiﬁ cant 
immunological memory responses with a large 
enhancement of glycoprotein-speciﬁ c antibodies were 
found, which were signiﬁ cantly higher than non-boosted 
responses. However, the boosting eﬀ ects to T-cell 
immunogenicity were relatively few. 
Compared with the results from previous studies, 
heterologous prime-boost regimens consisting of 
two diﬀ erent viral vectors seemed to be more eﬀ ective to 
minimise the negative eﬀ ect on the response to the vectors 
and can elicit stronger cellular immune responses to the 
gene inserts than homologous regimens.18–20 Therefore, 
the relatively weak boosting eﬀ ect of T-cell response is a 
major concern about the homologous boosting regimen 
with adenovirus type-5 Ebola virus vaccine applied in our 
study. Although rodents and NHPs challenge studies 
showed that induction of both antibodies and CD8 T-cell 
responses was potentially protective against Ebola virus 
disease,1,21 later studies found that the humoral immune 
response without CD8 T-cell response still provided high 
survival after Ebola virus challenge, suggesting Ebola 
glycoprotein-speciﬁc antibodies alone might be suﬃ  cient 
for protection.22–24 Therefore, the magnitude of humoral 
immune responses enhanced by the homologous 
adenovirus 5-vectored booster in our study was quite 
encouraging. Additionally, the protective level of antibody 
needed for most human beings might not be as high as 
that in NHP challenging models, because human beings 
are likely to be infected with smaller quantities of virus via 
diﬀ erent routes in natural exposure to the Ebola virus. A 
lower antibody response might therefore still be protective 
for human beings. A vaccine might not be able to oﬀ er 
100% protection, but protection around 50–70% might be 
suﬃ  cient to help control an Ebola outbreak.
A limitation of this study is that adenovirus type-5 vector 
vaccine platform could be compromised by the pre-existing 
immunity against the vector, since a large proportion of 
adults have pre-existing adenovirus type-5 immunity 
worldwide.22–24 The presence of pre-existing anti-adenovirus 
type 5 neutralising antibodies could not only signiﬁ cantly 
blunt the vaccine-elicited speciﬁ c humoral and cell 
response against Ebola glycoprotein, but also weaken the 
persistence of the vaccine-elicited immunity. However, our 
results suggested that the negative eﬀ ect of pre-existing 
immunity to adenovirus type-5 vector could be partly 
relieved by increasing the dose of the adenovirus type-5 
vector Ebola virus vaccine administered.
 Another limitation of this study is that homologous 
prime-boost regimen is generally considered as less 
eﬀ ective as a heterologous prime-boost regimen. Our 
absence of access to other Ebola virus vaccine candidates 
besides the adenovirus type-5 Ebola virus vaccine 
prevented us from studying the immunogenicity of a 
heterologous prime-boost regimen. Nevertheless, the 
homologous prime-boost regimen with the adenovirus 
type-5 Ebola virus vaccines seemed powerfully 
immunogenic in our study, showing ability to induce 
high and durable speciﬁ c humoral responses, but not the 
cellular immunity responses. However, the 6-month 
interval between prime and boost might not be optimal, 
since the Ebola glycoprotein-speciﬁc antibodies measured 
in the vaccine recipients already declined to less than 1000 
at day 112. These results might suggest a demand for a 
better immunisation regimen with a shorter prime-boost 
interval, but the eﬀ ect of pre-existing adenovirus type-5 
neutralising antibodies at diﬀ erent boosting timepoints 
should be considered. Although a longer prime-boost 
interval was associated with a higher boosting response, 
such a long-interval regimen might not facilitate vaccine 
deployment.4 Therefore, the booster vaccination at other 
prime-boost intervals or with a heterologous Ebola 
vaccine such as DNA vaccine or recombinant subunit 
vaccine needs to be investigated in future studies.
 Although the data presented here suggest acceptable 
safety and good immunogenicity of the adenovirus 
5-vectored Ebola vaccine and the potential beneﬁ ts from 
the boosting regimen as compared with single dose 
priming alone, results from this phase 1 study in a few 
healthy adults from a small area in China could be 
limited in generalisability. Since the safety and 
immunogenicity of this vaccine in the Ebola-risk 
population in Africa are more crucial, a phase 2 study of 
the adenovirus 5-vectored Ebola vaccine in Sierra Leone 
began in October, 2014.25
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